4.160USD-2.57%Mkt Cap: 326.55M USDP/E: —Last update: 2026-05-26
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver m…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap326.55M USD
Enterprise Value281.03M USD
Revenue (TTM)16.72M USD
Gross Profit16.72M USD
Net Income (TTM)-99.50M USD
Revenue/Share0.2130 USD
Last Price4.160 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees79
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.20
PEG—
EV/EBITDA-3.46
EV/Revenue16.81
P/S20.63
P/B4.53
EPS (TTM)-1.00
EPS (Forward)-0.83
52W Range
0.750071% of range5.540
52W High5.540 USD
52W Low0.7500 USD
Profitability
Gross Margin100.00%
Oper. Margin-309.54%
EBITDA Margin0.00%
Profit Margin-819.59%
ROE-144.96%
ROA-70.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-56.30M USD
CapEx (TTM)67.00K USD
FCF Margin-107.24%
FCF Yield-5.49%
Net Debt-63.83M USD
Net Debt/EBITDA0.79
Balance Sheet
Debt/Equity0.26
Current Ratio2.03
Quick Ratio1.96
Book Value/Sh0.9550 USD
Cash/Share1.024 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.64.92M
Float22.96M
Insiders13.80%
Institutions64.09%
Short Interest
Short Ratio3.4d
Short % Float6.18%
Short % Out.1.95%
Shares Short1.55M
Short (prev mo.)2.32M
Technical
SMA 504.127 (+0.8%)
SMA 2002.362 (+76.1%)
Beta1.10
S&P 52W Chg28.31%
Avg Vol (30d)513.86K
Avg Vol (10d)378.40K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—